These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33133304)

  • 1. Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers.
    Khalifa O; Errafii K; Al-Akl NS; Arredouani A
    Dis Markers; 2020; 2020():8822859. PubMed ID: 33133304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease.
    Zaiou M
    World J Gastroenterol; 2022 Sep; 28(35):5111-5128. PubMed ID: 36188722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC.
    Rusu I; Pirlog R; Chiroi P; Nutu A; Puia VR; Fetti AC; Rusu DR; Berindan-Neagoe I; Al Hajjar N
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease.
    Huang R; Duan X; Fan J; Li G; Wang B
    Biomed Res Int; 2019; 2019():8690592. PubMed ID: 30931332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact and role of identified long noncoding RNAs in nonalcoholic fatty liver disease: A narrative review.
    Shi N; Sun K; Tang H; Mao J
    J Clin Lab Anal; 2023 Jun; 37(11-12):e24943. PubMed ID: 37435630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review.
    Zhang X; Asllanaj E; Amiri M; Portilla-Fernandez E; Bramer WM; Nano J; Voortman T; Pan Q; Ghanbari M
    Eur J Clin Invest; 2021 May; 51(5):e13479. PubMed ID: 33350463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNAs in nonalcoholic fatty liver disease and liver fibrosis: state-of-the-art and perspectives in diagnosis and treatment.
    De Vincentis A; Rahmani Z; Muley M; Vespasiani-Gentilucci U; Ruggiero S; Zamani P; Jamialahmadi T; Sahebkar A
    Drug Discov Today; 2020 Jul; 25(7):1277-1286. PubMed ID: 32439605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease.
    Liu XL; Cao HX; Fan JG
    J Dig Dis; 2016 Nov; 17(11):708-715. PubMed ID: 27628945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease.
    Aggeletopoulou I; Kalafateli M; Tsounis EP; Triantos C
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA in Non-alcoholic fatty liver disease.
    Rohilla S; Kaur S; Puria R
    Adv Clin Chem; 2022; 110():1-35. PubMed ID: 36210072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Fang Z; Dou G; Wang L
    Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease.
    Ashraf NU; Altaf M
    Mutat Res Rev Mutat Res; 2018; 778():1-12. PubMed ID: 30454678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease.
    Zaiou M
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circular RNAs as Potential Biomarkers and Therapeutic Targets for Metabolic Diseases.
    Zaiou M
    Adv Exp Med Biol; 2019; 1134():177-191. PubMed ID: 30919338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics and epigenetics purpose in nonalcoholic fatty liver disease.
    Botello-Manilla AE; Chávez-Tapia NC; Uribe M; Nuño-Lámbarri N
    Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):733-748. PubMed ID: 32552211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
    Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
    Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenging role of micro-RNAs in non-alcoholic fatty liver disease in children with obesity: is it time for a new era?
    Bartiromo M; Nardolillo M; Ferrara S; Russo G; Miraglia Del Giudice E; Di Sessa A
    Expert Rev Gastroenterol Hepatol; 2023; 17(8):817-824. PubMed ID: 37497846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
    Sun C; Fan JG; Qiao L
    Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
    Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
    World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.